Table 3.
AMPK mRNA expression
| Type 2 diabetes (n = 5–7) | Healthy control (n = 6–9) | |||
|---|---|---|---|---|
| AMPK | UT leg | T leg | UT leg | T leg |
| α1 | 0.13 ± 0.05 | 0.11 ± 0.04 | 0.18 ± 0.05 | 0.13 ± 0.06 |
| α2 | 0.17 ± 0.08 | 0.16 ± 0.11 | 0.21 ± 0.07 | 0.19 ± 0.08 |
| β1 | 0.10 ± 0.03 | 0.12 ± 0.03 | 0.14 ± 0.02 | 0.15 ± 0.02 |
| β2 | 0.14 ± 0.06 | 0.18 ± 0.07 | 0.23 ± 0.06 | 0.22 ± 0.06 |
| γ1 | 0.11 ± 0.03 | 0.09 ± 0.02 | 0.14 ± 0.02 | 0.16 ± 0.03 |
| γ2 | 0.28 ± 0.14 | 0.30 ± 0.10 | 0.32 ± 0.05 | 0.29 ± 0.05 |
| γ3 | 0.29 ± 0.07 | 0.15 ± 0.04* | 0.19 ± 0.02 | 0.11 ± 0.02* |
AMPK subunit isoform mRNA content in untrained (UT) or trained (T) human muscle biopsies from patients with type 2 diabetes or control subjects. Values are presented as the ratio between the mRNA of interest and cDNA content, and are given as mean ± s.e.m.
*
Significant difference (main effect) between UT and T (P = 0.008).